blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2130048

EP2130048 - APEX AS A MARKER FOR LUNG CANCER [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  22.02.2013
Database last updated on 03.10.2024
Most recent event   Tooltip17.07.2015Lapse of the patent in a contracting state
New state(s): HU		published on 19.08.2015  [2015/34]
Applicant(s)For all designated states
F. Hoffmann-La Roche AG
Grenzacherstraße 124
4070 Basel / CH
For:DE 
Roche Diagnostics GmbH
Sandhofer Strasse 116
68305 Mannheim / DE
[N/P]
Former [2009/50]For all designated states
F. Hoffmann-La Roche AG
Grenzacherstrasse 124
4070 Basel / CH
For:DE 
Roche Diagnostics GmbH
Sandhofer Strasse 116
68305 Mannheim / DE
Inventor(s)01 / HAGMANN, Marie-Luise
Saalangerstr. 42
82377 Penzberg / DE
02 / KARL, Johann
Bert-Schratzlseer-Str. 7
82380 Peissenberg / DE
03 / KLOECKNER, Julia
Kleinstrasse 3
81379 München / DE
04 / ROESSLER, Markus
Eichenstr. 9a
82110 Germering / DE
05 / TACKE, Michael
Geisenfelderstr. 7
80689 München / DE
06 / THIEROLF, Michael
Haydnweg 4
88400 Biberach / DE
 [2009/50]
Representative(s)Weiss, Wolfgang, et al
Weickmann & Weickmann
Patent- und Rechtsanwälte PartmbB
Postfach 860 820
81635 München / DE
[N/P]
Former [2009/50]Weiss, Wolfgang, et al
Weickmann & Weickmann Patentanwälte Postfach 86 08 20
81635 München / DE
Application number, filing date08716640.119.03.2008
[2009/50]
WO2008EP02224
Priority number, dateEP2007000607923.03.2007         Original published format: EP 07006079
[2009/50]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2008116592
Date:02.10.2008
Language:EN
[2008/40]
Type: A1 Application with search report 
No.:EP2130048
Date:09.12.2009
Language:EN
The application published by WIPO in one of the EPO official languages on 02.10.2008 takes the place of the publication of the European patent application.
[2009/50]
Type: B1 Patent specification 
No.:EP2130048
Date:18.04.2012
Language:EN
[2012/16]
Search report(s)International search report - published on:EP02.10.2008
ClassificationIPC:G01N33/574, G01N33/573
[2009/50]
CPC:
G01N33/57423 (EP,US); G01N33/57488 (EP,US); G01N2333/988 (EP,US)
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MT,   NL,   NO,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2009/50]
TitleGerman:APEX ALS MARKER FÜR LUNGENKREBS[2009/50]
English:APEX AS A MARKER FOR LUNG CANCER[2009/50]
French:APEX COMME MARQUEUR POUR LE CANCER DU POUMON[2009/50]
Entry into regional phase04.09.2009National basic fee paid 
04.09.2009Designation fee(s) paid 
04.09.2009Examination fee paid 
Examination procedure04.09.2009Examination requested  [2009/50]
02.07.2010Despatch of a communication from the examining division (Time limit: M04)
14.09.2010Reply to a communication from the examining division
04.11.2011Communication of intention to grant the patent
07.02.2012Fee for grant paid
07.02.2012Fee for publishing/printing paid
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  02.07.2010
Opposition(s)21.01.2013No opposition filed within time limit [2013/13]
Fees paidRenewal fee
08.03.2010Renewal fee patent year 03
10.03.2011Renewal fee patent year 04
07.03.2012Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU19.03.2008
BE18.04.2012
CY18.04.2012
CZ18.04.2012
DK18.04.2012
EE18.04.2012
FI18.04.2012
HR18.04.2012
LT18.04.2012
LV18.04.2012
MT18.04.2012
NL18.04.2012
PL18.04.2012
RO18.04.2012
SE18.04.2012
SI18.04.2012
SK18.04.2012
TR18.04.2012
BG18.07.2012
NO18.07.2012
GR19.07.2012
IS18.08.2012
PT20.08.2012
[2015/34]
Former [2015/32]BE18.04.2012
CY18.04.2012
CZ18.04.2012
DK18.04.2012
EE18.04.2012
FI18.04.2012
HR18.04.2012
LT18.04.2012
LV18.04.2012
MT18.04.2012
NL18.04.2012
PL18.04.2012
RO18.04.2012
SE18.04.2012
SI18.04.2012
SK18.04.2012
TR18.04.2012
BG18.07.2012
NO18.07.2012
GR19.07.2012
IS18.08.2012
PT20.08.2012
Former [2014/32]BE18.04.2012
CY18.04.2012
CZ18.04.2012
DK18.04.2012
EE18.04.2012
FI18.04.2012
HR18.04.2012
LT18.04.2012
LV18.04.2012
MT18.04.2012
NL18.04.2012
PL18.04.2012
RO18.04.2012
SE18.04.2012
SI18.04.2012
SK18.04.2012
BG18.07.2012
NO18.07.2012
GR19.07.2012
IS18.08.2012
PT20.08.2012
Former [2013/34]BE18.04.2012
CY18.04.2012
CZ18.04.2012
DK18.04.2012
EE18.04.2012
FI18.04.2012
HR18.04.2012
LT18.04.2012
LV18.04.2012
NL18.04.2012
PL18.04.2012
RO18.04.2012
SE18.04.2012
SI18.04.2012
SK18.04.2012
BG18.07.2012
NO18.07.2012
GR19.07.2012
IS18.08.2012
PT20.08.2012
Former [2013/10]BE18.04.2012
CY18.04.2012
CZ18.04.2012
DK18.04.2012
EE18.04.2012
FI18.04.2012
HR18.04.2012
LT18.04.2012
LV18.04.2012
NL18.04.2012
PL18.04.2012
RO18.04.2012
SE18.04.2012
SI18.04.2012
SK18.04.2012
NO18.07.2012
GR19.07.2012
IS18.08.2012
PT20.08.2012
Former [2013/09]BE18.04.2012
CY18.04.2012
DK18.04.2012
EE18.04.2012
FI18.04.2012
HR18.04.2012
LT18.04.2012
LV18.04.2012
NL18.04.2012
PL18.04.2012
SE18.04.2012
SI18.04.2012
NO18.07.2012
GR19.07.2012
IS18.08.2012
PT20.08.2012
Former [2013/08]BE18.04.2012
CY18.04.2012
DK18.04.2012
FI18.04.2012
HR18.04.2012
LT18.04.2012
LV18.04.2012
NL18.04.2012
PL18.04.2012
SE18.04.2012
SI18.04.2012
NO18.07.2012
GR19.07.2012
IS18.08.2012
PT20.08.2012
Former [2013/04]BE18.04.2012
CY18.04.2012
FI18.04.2012
HR18.04.2012
LT18.04.2012
LV18.04.2012
PL18.04.2012
SE18.04.2012
SI18.04.2012
NO18.07.2012
GR19.07.2012
IS18.08.2012
PT20.08.2012
Former [2013/01]CY18.04.2012
FI18.04.2012
HR18.04.2012
LT18.04.2012
LV18.04.2012
PL18.04.2012
SE18.04.2012
SI18.04.2012
NO18.07.2012
GR19.07.2012
IS18.08.2012
PT20.08.2012
Former [2012/51]CY18.04.2012
FI18.04.2012
HR18.04.2012
LT18.04.2012
LV18.04.2012
PL18.04.2012
SE18.04.2012
SI18.04.2012
NO18.07.2012
GR19.07.2012
IS18.08.2012
Former [2012/50]CY18.04.2012
FI18.04.2012
HR18.04.2012
LT18.04.2012
LV18.04.2012
PL18.04.2012
SE18.04.2012
NO18.07.2012
GR19.07.2012
IS18.08.2012
Former [2012/49]CY18.04.2012
FI18.04.2012
LT18.04.2012
PL18.04.2012
SE18.04.2012
NO18.07.2012
IS18.08.2012
Former [2012/48]FI18.04.2012
LT18.04.2012
SE18.04.2012
NO18.07.2012
Former [2012/47]LT18.04.2012
NO18.07.2012
Cited inInternational search[DXY]WO9747971  (ADVANCED RES & TECH INST [US], et al) [DX] 1-6 * the whole document * * in particular: claims 1,3,4,6,11-15,17,18. * [Y] 7-10;
 [DXY]WO02076280  (YEDA RES & DEV [IL], et al) [DX] 1-6 * the whole document * * in particular: claims 1-5,16,37-41. * [Y] 7-10;
 [DA]  - PUGLISI F ET AL, "Prognostic significance of Ape1/ref-1 subcellular localization in non-small cell lung carcinomas.", ANTICANCER RESEARCH, (200111), vol. 21, no. 6A, pages 4041 - 4049, XP008083956 [DA] 1-10 * the whole document * * in particular: abstract; p.4043, col.1, par.3; p.4044, col.2, par.5; fig.3. *
 [YA]  - SCHNEIDER J, "Tumor markers in detection of lung cancer.", ADVANCES IN CLINICAL CHEMISTRY, (2006), vol. 42, pages 1 - 41, XP008083971 [Y] 7-10 * the whole document * * in particular: section 6 spanning p.6+7. * [A] 2-5
 [YA]  - MOLINA R ET AL, "Pro-gastrin-releasing peptide (proGRP) in patients with benign and malignant diseases: comparison with CEA, SCC, CYFRA 21-1 and NSE in patients with lung cancer.", ANTICANCER RESEARCH, (200505), vol. 25, no. 3A, pages 1773 - 1778, XP008083991 [Y] 7-10 * the whole document * * in particular: abstract. * [A] 2-5
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.